Due to the Market BIT225 is worth $Billions, page-9

Yes I have had similar musings as well.

Here's an interesting little story that came up in my personal DD before going all in on BITOB.

Many years ago I lived in Berlin (hence my nic) and I was head of sponsorship sales for central Europe for a huge exhibition and conference company called IQPC.

One of the conferences we used to run had the bewildering title of Polymorphism and Crystallization and dealt with the drug discovery process from the perspective of pharma companies. I booked loads of sponsors and exhibitors from companies who created drug discovery library software. During the conference as well I got to spend several days with some of the white coat wearers and was able to ask loads of questions and increase my knowledge on the drug discovery business which has been quite useful for me with regard to BIT.

The producer of the conference was a very clever German guy with a degree in Chemistry who has since gone on to work for one of the big German pharma firms where he oversees numerous drug discovery programs. I am still quite good friends with this guy and we have been discussing BIT's latest ANNs and what it could mean for adoption of the tech into the discovery pipelines of big pharma.

Anyway this is the background to what follows...

My clued up friend in Berlin has suggested to me that given that the BIT compound works at the cellular microphage level there is the strong possibility of multiple licenses being made available with each having its own stage 3 trial.

For example one firm could license it and trial stage 3 for HIV, another could license it and start stage 3 for .. say Ebola, another for Dengue fever,and so on and so on. Each license holder would fund their own stage 3 for their specific interest and then subject to it being approved by the FDA and equivalent bodies worldwide the revenue stream would be shared between the pharma firm and BIT. In essence the pharma equivalant of owning David Bowie's back catalogue from a royalty basis. Such an outcome would make BIT worth unimaginable amounts of money and certainly multi-multi bags from where we are now

He seemed to think it unlikely that one big pharma firm would take it on for all possible uses.

He said a takeover bid for BIT from big pharama would make sense but that shareholders would be barmy to sell if the stage 2 results are as solid as claimed.

If that little theory is correct then we could see ANNs during the remainder of this year setting out stage 3 trial agreements with numerous big pharma firms.

Please note that I am a bit out of my depth here but I would be delighted if someone with substantially more technical expertise than me in the drug discovery process could comment on this post.

EB